Key result
Bioprosthetic AVR in recent years is linked to ~59% lower short-term mortality than early cohorts.
Why the study?
Nationwide changes in procedure rates, patient selection, and prognosis after surgical aortic valve replacement over time were not well characterized.
What are the population trends in procedure rates, patient selection, and prognosis after surgical aortic valve replacement in Finland between 2001 and 2016?
Observational (n=12,139)
Yes
What are the population trends in procedure rates, patient selection, and prognosis after surgical aortic valve replacement in Finland between 2001 and 2016?
Between 2001 and 2016 in Finland, the use of biological aortic valves increased significantly and short-term mortality decreased, despite an increasing patient comorbidity burden.
Rising biologic SAVR use coincided with lower short-term mortality despite rising comorbidities in Finnish registry; leaves open selection effects and optimal prosthesis choice.
Objectives. To investigate nationwide changes in procedure rates, patient selection, and prognosis after all surgical aortic valve replacements. Design. Patients undergoing primary surgical aortic valve replacement between 2001 and 2016 were identified from three nationwide registers with compulsory reporting to examine trends in aortic valve surgery over four four-year time periods. Results. A total of 12,139 surgical aortic valve replacement procedures (mean age 61.9 ± 11.8 years, 39.1% women) were performed. The total number of biological valves increased from 1001 (42.9%) to 2526 (75.5%) from 2001–2004 to 2013–2016 (p < .001). During the first and last time periods the comorbidity burden increased; share of patients with hypertension increased from 37.5% to 46.9% (p < .001), diabetes from 14% to 16.5% (p = .01) and previous stroke from 5.2% to 7.2% (p = .01). The proportion of women undergoing surgery decreased from 40% to 36.1% from 2001–2004 to 2013–2016, respectively (p = .01). Overall 28-day mortality was 3.5%. In patients with biologic valve the multivariable-adjusted risk of short-term mortality decreased steadily in every four-year period from 2001–2004 to 2005–2008 (HR, 0.66; 95% CI 0.47–9.92), 2009–2012 (HR, 0.54; 95% CI, 0.39–0.75) and 2013–2016 (HR, 0.41; 95% CI, 0.29–0.58), whereas short-term mortality remained similar in patients with mechanical valve. The risk of four-year postoperative mortality after all surgical aortic valve replacements stayed constant. Conclusions. The use of biologic aortic valve prosthesis has increased from 2001 to 2016. The proportion of women has declined markedly. The short-term mortality has decreased and the long-term mortality has stayed constant despite increasing comorbidity burden.
No takes yet. Share an insight, caveat, or question.
Myllykangas et al. (2019) conducted an observational in Surgical aortic valve replacement (n=12,139). Biologic aortic valve replacement in 2013-2016 vs. Biologic aortic valve replacement in 2001-2004 was evaluated on Short-term mortality (HR 0.41, 95% CI 0.29-0.58). Among patients receiving biologic aortic valves, the risk of short-term mortality decreased significantly in 2013-2016 compared to 2001-2004 (HR 0.41; 95% CI 0.29-0.58).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: